| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Immunology Program, Kimmel Cancer Center [B. K. H., E. C. L.] and Department of Medicine [H. C. M., E. C. L.], Division of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107; and Department of Surgery, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, New Brunswick, NJ 08901 [E. C. L.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding ß-galactosidase (ß-gal) is injected into the tumors of normal mice, no ß-gal-specific IFN- response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong ß-gal-specific, IFN- response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
IL-103 is a type 2-associated cytokine that has been shown to inhibit the development of cellular immune responses via a number of mechanisms. Perhaps the best characterized of these is the ability to inhibit antigen-induced T cell proliferation indirectly by down-regulating molecules found on professional APCs, which are essential for T-cell activation (6, 7, 8) . IL-10 also inhibits inflammatory cytokine synthesis by macrophages directly and can inhibit human T cell proliferation directly by blocking IL-2 production at the transcriptional level (9 , 10) . Furthermore, recent studies by Groux et al. (11) demonstrate that activation of antigen-specific T cells in the presence of IL-10 drives the differentiation of these cells toward a T-helper phenotype that is capable of blocking T-cell proliferation both in vitro and in vivo. Thus, through a variety of mechanisms, IL-10 can prevent the generation of a productive cellular immune response.
We and others have reported the presence of IL-10 at the site of progressively growing tumors in a variety of human cancers, including melanoma, non-small cell lung carcinoma, renal cell carcinoma, and bladder cancer (12, 13, 14, 15, 16) . Moreover, increased IL-10 serum levels have been reported in patients with melanoma, renal cell carcinoma, and pancreatic, gastric, and colon adenocarcinoma (17 , 18) . Given the well-documented capability of IL-10 to suppress cellular immune responses, one might speculate that the observed IL-10 allows for progressive tumor growth by preventing the generation of a tumor-specific cellular immune response. However, efforts to test this hypothesis have yielded contradictory results. Studies have shown that IL-10 suppresses the tumoricidal activity of macrophages (19) , inhibits cytotoxicity and cytokine production by tumor-specific T cells (20) , and blocks the presentation of tumor antigens by APCs (21) . These findings support the view that IL-10 plays a role in suppressing tumor-specific immune responses and thus increases tumorigenicity. In contrast, several studies using tumors genetically engineered to produce IL-10 have shown that constitutive IL-10 production at the tumor site can stimulate a tumor-specific immune response and thereby decrease tumorigenicity (22, 23, 24, 25) .
The discrepancy between these findings is intriguing and remains to a large degree unresolved. It is important to consider that the majority of studies demonstrating an immunostimulatory role for IL-10 have used tumors engineered to produce IL-10 by gene transfection, which may not mimic the natural production of IL-10 accurately in terms of concentration, timing, and location. Nevertheless, in vivo models directly demonstrating a role for IL-10 in the suppression of antitumor immunity remain limited. Here we describe a tumor cell line that does not produce IL-10 in vitro but is associated with IL-10 in vivo, suggesting that it induces infiltrating cells to produce IL-10. By comparing the behavior of this tumor in normal versus IL-10 KO mice, whose infiltrating cells are unable to produce IL-10, we provide the first in vivo evidence that tumor-induced IL-10 can prevent the generation of a type 1 immune response directed at a tumor-associated antigen. We report that in the absence of IL-10, animals show prolonged survival and an increased frequency of tumor rejection. Finally, we demonstrate that the immunosuppressive effects of tumor-induced IL-10 are not limited to the tumor antigen, but can also block the induction of a type 1 immune response specific for a non-tumor antigen present at the tumor site.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
RT-PCR.
Total RNA was extracted from cells or tissues using TRIZOL Reagent (Life Technologies, Inc., Gaithersburg, MD). cDNA synthesis was performed by incubating 5 µg of total RNA in diethyl pyrocarbonate-treated water, Random Primers (Life Technologies), and reverse transcription buffer (Life Technologies) at 65°C for 10 min and then cooling the mixture immediately to 4°C. To this mixture, 10 mM DTT (Life Technologies); 2.5 mM each of dATP, dCTP, dGTP, and dTTP (Life Technologies); and 500 U of MMLV-RT (Life Technologies) were added to achieve a final sample volume of 50 µl. To complete the reverse transcription, samples were incubated at 37°C for 1 h.
For PCR, 5 µl of cDNA were heated to 95°C for 5 min and then combined with PCR Reaction Buffer (Fisher Scientific, Pittsburgh, PA); 2.5 mM each of dATP, dCTP, dGTP, and dTTP (Fisher Scientific); 1.25 U of Taq DNA Polymerase (Fisher Scientific); 1.5 mM MgCl2 (Fisher Scientific); and 0.5 µM of the appropriate primer pair in MicroAmp reaction tubes (Perkin-Elmer, Norwalk, CT) to achieve a final sample volume of 50 µl. Amplification of samples was performed using the GeneAmp System 9600 thermocycler (Perkin-Elmer). Each sample was denatured at 94°C for 30 s, annealed at 55°C for 30 s, and extended at 72°C for 30 s for 30 cycles. This was followed by a 10-min extension at 72°C. PCR products were analyzed by electrophoresis on a 1.8% agarose gel and stained with ethidium bromide. Size markers (100-bp ladder; Life Technologies) were run adjacent to samples to confirm that PCR products were the expected sizes for each set of primers. Primer pairs used were as follows: HY sense, AAA TGC AGC TCG GAC CAA ATC; HY antisense, CTG AAT GAT GTG AAG CTG TC; ß-actin sense, TGG AAT CCT GTG GCA TCC ATG AAA C; and ß-actin antisense, TAA AAC GCA GCT CAG TAA CAG TCC G.
HY Restimulation Experiments.
Female mice were immunized subcutaneously in the flank with either 50 x 106 syngeneic male splenocytes or 1 x 106 MB49 cells. After 2 weeks, the mice were sacrificed and the spleens removed. After pooling at least two spleens per group, splenocytes were isolated by repeated flushing with PBS followed by passage through a 40 mesh CELLECTOR screen (Thomas Scientific, Swedesboro, NJ). Splenocytes (7 x 106) were restimulated with syngeneic female or male splenocytes (3 x 106) in duplicate wells of a 24-well plate, in a total of 2 ml of complete medium supplemented with 2-mercaptoethanol. Restimulation cultures were carried on for 3 days at 37°C, 5% CO2, at which point supernatants from duplicate wells were pooled and analyzed for IFN-, IL-4, and IL-10 by ELISA, using paired antibodies purchased from PharMingen (San Diego, CA). As a positive control for our IL-4 ELISA, MB49 cells were infected for 2 h with a vaccinia virus-IL-4 construct (made in our laboratory) and then cultured overnight to allow for IL-4 secretion by infected cells. Supernatants from these cultures were assayed for IL-4 on the same plates as experimental supernatants to confirm that the IL-4 assay was functioning properly. The detection limit of our assay is 30 pg/ml.
Determination of IL-10 at Tumor Site in Vivo.
Female C57BL/6 and female IL-10 KO mice were immunized subcutaneously in the flank with 1 x 106 MB49 cells. After 2 weeks, the mice were sacrificed and the tumors removed. Tumor masses were homogenized into a single cell suspension using a Pyrex tissue grinder followed by passage through a 70 µm nylon cell strainer. Single cell suspensions derived from tumors, as well as MB49 cells grown exclusively in vitro, were cultured at 5 x 106 cells/well in a total of 2 ml complete medium in 24-well plates overnight at 37°C, 5% CO2. Supernatants from duplicate wells were pooled and analyzed for IL-10 by ELISA, using paired antibodies purchased from PharMingen.
Tumor Growth Experiments.
Female C57BL/6 mice and female IL-10 KO mice were injected subcutaneously in the flank with 1 x 106 MB49 cells. Cages were given numerical codes to blind the experiment. Tumor size was measured every 2–3 days with metric calipers by measuring the two largest diameters. Mice were sacrificed when one diameter of the tumor became >1.5 cm because at this point mice consistently became sick and lethargic. In our experience, no tumor with a single diameter >0.75 cm has ever been observed to regress. The experiment was unblinded, and Kaplan-Meier survival curves were tested for statistically significant differences, using the Mantel-Haenszel test for comparison of survival curves. Analysis was performed using WINKS Statistical Data Analysis software (TexaSoft, Cedar Hill, TX).
ß-Gal Immunization.
Female C57BL/6 mice and female IL-10 KO mice were immunized subcutaneously in the flank with 1 x 106 MB49 cells. After 10 days, mice were injected with 1–2 x 106 pfu recombinant vaccinia virus expressing the ß-galactosidase gene (vv/ß-gal; provided by Dr. Laurence Eisenlohr, Thomas Jefferson University, Philadelphia, PA) in a total of 100 µl directly into the tumor mass or subcutaneously into the flank opposite the tumor. Control mice were injected with 1–2 x 106 pfu vv/ß-gal subcutaneously into the flank. Eight days after the vv/ß-gal inoculation, the mice were sacrificed and the spleens removed. After at least two spleens were pooled per group, splenocytes were isolated as described above and restimulated (4 x 106) in quadruplicate wells of a 24-well plate with 20, 10, 5, or 0 µg/ml soluble ß-gal (Sigma Chemical, St. Louis, MO) in a total of 2 ml of complete medium supplemented with 2-mercaptoethanol. Restimulation cultures were performed for 3 days at 37°C, 5% CO2, and supernatants from quadruplicate wells were pooled and analyzed for IFN-, IL-4, and IL-10 by ELISA, using paired antibodies purchased from PharMingen. As a positive control for our IL-4 ELISA, supernatants from MB49 cells infected with a vaccinia virus-IL-4 construct were used as described above.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, MB49 expresses HY mRNA when grown in vitro (Lane 3) and in vivo (Lane 4). Furthermore, although MB49 tumors grow progressively in both male and female mice, immunization of female mice with syngeneic male spleen cells protects against tumor growth upon subsequent challenge with MB49.4
This indicates that in addition to gene expression, MB49 expresses the HY antigen in a manner that is recognizable by the immune system of syngeneic female mice. The expression of HY by MB49 and its growth in female mice enabled us to use HY as a surrogate tumor antigen in subsequent studies.
|
) Response in Normal Female Mice., and the type 2 cytokines, IL-4 and IL-10. Fig. 2
shows that immunization with male spleen cells leads to a male-specific, IFN- response (Fig. 2A)
with very low levels of the type 2 cytokine IL-10 (Fig. 2B)
. IL-4 was not detectable in these cultures, despite our ability to detect IL-4 in positive-control supernatants assayed in parallel (see "Materials and Methods"). Because MB49 expresses the HY antigen, it might be expected to elicit a similar HY-specific, type 1 immune response when injected into female mice. However, as shown in Fig. 2A
, immunization with MB49 followed by restimulation with male spleen does not elicit a comparable IFN- response. In contrast, IL-10 is produced in large quantities by splenocytes of MB49 immunized mice, although this IL-10 production does not appear to be HY-specific (Fig. 2B)
. As will be discussed below, because MB49 induces IL-10 production, we cannot conclude that the presence of IL-10 is an indication of a tumor-specific type 2 response. Rather, failure to detect IL-4 would suggest that no tumor-specific type 2 response is mounted.
|
), and the association of IL-10 with a myriad of other types of cancer, we sought to determine whether IL-10 was present at the tumor site in our MB49 system.
IL-10 is not detectable in supernatants of the MB49 cell line when tested by ELISA (Fig. 3)
. The absence of IL-10 production in vitro, however, does not preclude the presence of this cytokine at the site of MB49 tumors in vivo. In fact, other groups have reported that tumors are capable of producing soluble factors that induce host cells to produce IL-10 (31
, 32)
. To determine whether the growth of MB49 induces IL-10 production in vivo, normal and IL-10 KO mice were injected with 1 x 106 MB49 cells subcutaneously. Two weeks later, tumors were removed, homogenized into single cell suspensions, and put into culture for 18 h. IL-10 was measured in culture supernatants by ELISA. If MB49 is capable of inducing IL-10 production by infiltrating cells, we predicted that only cell suspensions derived from normal mice would secrete IL-10 because infiltrating cells in IL-10 KO mice are genetically incapable of IL-10 production. As shown in Fig. 3
, single cell suspensions derived from tumors established in normal mice secrete IL-10, whereas those derived from IL-10 KO mice do not. These data suggest that although MB49 does not produce IL-10 in vitro or in vivo, it induces infiltrating cells to produce IL-10. The possibility remains that a factor present in normal, but not IL-10 KO, mice induces MB49 to produce IL-10 in vivo, and it is with this caveat that we use the phrase "tumor-induced IL-10" throughout the article. However, we view this possibility as highly unlikely and, for the purposes of this study, the absence of IL-10 at the tumor site in the KOs (Fig. 3)
renders these animals a suitable model for study of the growth of MB49 in the absence of IL-10. The mechanism of IL-10 induction by MB49 presently is under investigation in our laboratory.
|
) Immune Response to MB49. response to MB49 (see Fig. 2A
), we compared the immune response to MB49 in normal versus IL-10 KO mice. Female C57Bl/6 normal or IL-10 KO mice were injected subcutaneously with either 50 x 106 syngeneic male spleen cells or 1 x 106 MB49 cells. After 2 weeks, the mice were sacrificed, the spleens removed, and the splenocytes placed into culture for three days with restimulation by either syngeneic female or male spleen cells. After 3 days in culture, the supernatants were removed and tested for both type 1 and type 2 cytokines by ELISA. Consistent with the results shown in Fig. 2
, normal mice do not mount an HY-specific IFN- response after tumor growth (Fig. 4)
, but do show nonspecific IL-10 production and no detectable IL-4 (data not shown). In contrast, IL-10 KO mice show a significant HY-specific IFN- response (Fig. 4)
. Increased nonspecific IFN- production (e.g., production after restimulation with female spleen) was also observed in IL-10 KO mice, consistent with the elevated spontaneous IFN- production seen by others in these animals (33
, 34)
. However, it is important that in six of seven similar experiments, IL-10 KO mice showed male-specific IFN- production, whereas normal mice showed a male-specific response in only two of seven similar experiments. These data suggest that the MB49-induced IL-10 is indeed responsible for the absence of a tumor-specific, type 1 immune response in normal mice.
|
. IL-10 KO mice also showed an enhanced ability to reject MB49 tumors when compared with normal mice. In normal mice, only 1 animal of 15 was able to reject the tumor, whereas all other tumors grew progressively to a size that required sacrifice of the animals (Table 1)
. In contrast, 6 of 15 IL-10 KO mice rejected the tumor completely (after initial tumor take) and remained tumor free for 11 weeks after tumor inoculation (Table 1)
. To assay for the presence of long-lived antitumor immunity, mice were rechallenged with an equivalent dose of MB49 as the original tumor challenge on the opposite flank. All mice that had rejected tumor previously were resistant to subsequent tumor challenge, whereas three of three naive normal controls developed progressively growing tumors (Table 1)
. Interestingly, three of three naive IL-10 KO controls grew tumors initially, but two of these three regressed completely (Table 1)
, consistent with the enhanced ability of IL-10 KO mice to reject primary tumor challenge described above.
|
|
) Immune Response Directed at a Non-Tumor Antigen Present at the Tumor Site.) response to ß-gal in mice (35)
. Thus, we used a vaccinia virus carrying the ß-gal gene (vv/ß-gal) to deliver ß-gal to the tumor site and then studied the effect of tumor-induced IL-10 on the generation of an immune response to ß-gal.
To confirm that immunization with vv/ß-gal would lead to a type 1 response under normal conditions, we injected vv/ß-gal subcutaneously into female C57BL/6 mice, waited 8 days, and then restimulated the splenocytes in vitro with soluble ß-gal. Three-day supernatants were tested by ELISA for IFN-, IL-10, and IL-4. As shown in Fig. 6A
, the expected ß-gal-specific IFN- response was observed. Injection of the same viral construct into a MB49 tumor mass (10 days after inoculation with tumor cells) resulted in no ß-gal-specific IFN- response. Consistent with prior experiments (see Fig. 2
), these MB49-bearing animals showed high levels of non-antigen-specific IL-10 and no detectable IL-4 (data not shown). In contrast, IL-10 KO mice showed a ß-gal-specific response after immunization with the vv/ß-gal even when immunization was performed directly into the MB49 tumor mass (Fig. 6A)
. These data suggest that the failure of normal, tumor-bearing mice to mount a type 1 response to vv/ß-gal present at the tumor site is due to tumor-induced IL-10.
|
, tumor-bearing mice mount a ß-gal-specific IFN- response that is equal to the response mounted by non-tumor-bearing controls, suggesting that the effects of IL-10 are local and do not result in global immune suppression in the tumor-bearing animal. |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
) immune response. We have shown that in vivo growth of MB49 is associated with IL-10 production, most likely by infiltrating host cells. Given this finding, the availability of IL-10 KO mice of the appropriate background, whose infiltrating cells are unable to produce IL-10, allowed us to study the effect of tumor-induced IL-10. In IL-10 KO mice, MB49 primes for an HY-specific, type 1 (IFN-) response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors after inoculation with MB49. These findings demonstrate that tumor-induced IL-10 can block the generation of a type 1 immune response directed against a tumor antigen and thereby can allow for progressive tumor growth. Finally, using a recombinant vaccinia virus vector to deliver a model antigen (ß-gal) to the tumor site, we show that the effects of tumor-induced IL-10 are not limited to the tumor antigen, but also suppress the generation of an immune response directed at a non-tumor antigen present at the tumor site.
The profile of cytokines produced during an immune response correlates with and may direct the response toward either cell-mediated immunity, termed type 1, which is marked by delayed-type hypersensitivity and CTLs, or humoral immunity, termed type 2, which is marked by antibody production. As the immune system has become more fully understood, it has become apparent that the type of immune response elicited is critical to the ultimate effectiveness of that response. This concept is best illustrated by the example of murine L. major. Resistant mouse strains mount a type 1 response (characterized by IFN-) to the parasite and effectively resolve the infection, whereas susceptible strains mount a type 2 response (characterized by IL-4 and IL-10) and as a result, die from infection (3)
. Responses to Mycobacterium leprae demonstrate that this same phenomenon exists in humans because patients with the lepromatous form of the disease display a type 2 response (IL-4 and IL-10), whereas patients with the milder tuberculoid form of disease show a type 1 response (IFN-; Ref. 36
). A more complete list of diseases where the Th1/Th2 dichotomy plays an important role can be found in a recent review by Mosmann and Sad (1)
.
In tumor systems, a type 1 response is thought to be most effective for the eradication of malignant cells. Aruga et al. (4) have demonstrated that CD3+ tumor-draining lymph node cells that secrete a type 1 profile of cytokines can mediate tumor regression in adoptive immunotherapy, whereas those expressing a type 2 cytokine profile are ineffective. In humans, spontaneous regression of melanoma has been correlated with the presence of an elevated type 1 cytokine profile at the tumor site (5) . Accordingly, we previously have proposed that one mechanism of immune escape used by tumors is the preferential production or induction of type 2 cytokines at the tumor site (12) . The presence of these type 2 cytokines might serve to suppress an effective type 1 antitumor response and/or to promote an ineffective type 2 response.
IL-10 is one such type 2 cytokine, which we and others have shown to be present in a wide variety of human cancers (12, 13, 14, 15, 16) . Through its effects on APCs, IL-10 can block the development of a type 1 response, thereby favoring the development of a type 2 response (6, 7, 8, 9, 10, 11) . The lack of tumor-specific IL-4 production in our studies indicates that there may not be development of a type 2 response in our system. Rather, we observe that IL-10 suppresses the generation of a tumor-specific type 1 response without a concomitant increase in a measurable type 2 response. This is consistent with several published reports of IL-10 acting as a strict suppressor of various stages of the immune response. First, it has been reported that IL-10 can block the accumulation of both macrophages and DCs at the tumor site (37 , 38) . Because these APCs are thought to be crucial for the initiation of any cell-mediated response, their absence could prevent the initiation of immune responses specific for tumor-associated antigens. Second, DCs that do reach the tumor site might be altered functionally as a consequence of exposure to IL-10. For example, studies have demonstrated that DCs treated with IL-10 show reduced capacity to stimulate T cells and are capable of inducing antigen-specific anergy (39) . Finally, tumor-specific T cells that become activated in the presence of IL-10 may differentiate into Tr1 cells, as has been suggested by Groux et al. (11) . These Tr1 cells have been shown to suppress immune responses both in vitro and in vivo. Determination of which of these or other mechanisms may be operative in our system is the focus of ongoing studies in our laboratory.
Our findings are consistent with several recent reports that suggest that IL-10 may interfere with antitumor immune responses in other transplantable tumor systems. Qin et al. (37) have shown that successful vaccination with granulocyte macrophage colony-stimulating factor gene-modified tumor cells occurs only when the IL-10 normally associated with this tumor is blocked by antisense. Failure to block this IL-10 results in a lack of recruitment of DCs to the tumor site. Donawho et al. (40) have demonstrated that the enhanced outgrowth of transplantable melanomas in UV-irradiated mice is due to IL-10. Finally, Hagenbaugh et al. (41) have reported that transgenic mice who overproduce IL-10 show accelerated tumor growth that can be slowed by addition of blocking antibody to IL-10. In the present study, we offer the first detailed analysis of the effect of tumor-induced IL-10 on the immune response directed against a tumor antigen. This is the first report in which the removal of tumor-induced IL-10 is itself sufficient to allow for the generation of a tumor-specific type 1 immune response and to allow for complete tumor rejection in up to 40% of animals.
Our data do not appear to be consistent with studies showing that transfection of tumors with the IL-10 gene leads to an increased antitumor immune response and decreased tumorigenicity (22, 23, 24, 25) . At least two points may explain this apparent conflict. First, it is important to note that the majority of studies correlating IL-10 with decreased tumorigenicity use IL-10-transfected tumors (22, 23, 24, 25) . Such transfected tumors may not reflect the natural production of IL-10 accurately in terms of concentration, timing, and location. We have circumvented this limitation by using a tumor that does not produce IL-10, but rather induces host cells to produce IL-10. By using this tumor in syngeneic IL-10 KO mice, we were able to study the effects of IL-10 "naturally" associated with the tumor. Our findings show that, in this context, IL-10 can indeed allow the tumor to avoid an immune response that might otherwise be directed against it. An alternative explanation is the possibility that different tumors are inherently different in their response to IL-10. These differences might be related to the presence or absence of other cytokines in the tumor microenvironment, which may influence the ultimate effect of IL-10, or may involve differential susceptibility to different effector mechanisms of the immune system. Therefore, it is conceivable that the differences observed between our system and the transfected-tumor systems may simply reflect inherent differences in the tumor systems studied.
The ability of tumor-induced IL-10 to inhibit the generation of immune responses at the tumor site has important implications with respect to local immunotherapy of cancer. To date, the only widely used form of local immunotherapy is intravesical BCG treatment of superficial bladder cancer following surgery. Although BCG is relatively effective at initiating a local inflammatory reaction, there is no evidence of tumor-specific cell-mediated immunity following treatment. Consistent with this are our own observations that treatment of intravesical MB49 with BCG does not lead to the induction of MB49-specific CTLs.5 A similar situation exists in melanoma, where only anecdotal evidence exists for the presence of systemic tumor-specific immune responses after localized treatment with BCG (42) . Our findings suggest that tumor-induced IL-10 may be one reason for the failure of BCG to elicit tumor-specific cell-mediated immunity. The presence (or absence) of other cytokines such as IL-2 and granulocyte macrophage colony-stimulating factor, although not examined in the present study, may also contribute to the overall effectiveness of immunotherapeutic treatments. These and other cytokines will be examined as we continue our analysis of the MB49 system.
Certain next-generation strategies of immunotherapy might also be limited by tumor-induced IL-10. Intralesional cytokine gene therapy, presently in clinical trials in our group for melanoma, is one such approach (43
, 44)
. The goal of such therapy is to stimulate the induction of tumor-specific immunity by providing cytokine(s) at the tumor site that are known to promote cell-mediated immunity. The effectiveness of such an approach might be severely limited if IL-10 is also present at the lesion site, potentially blocking or opposing the effects of the delivered cytokine(s). These limitations might be overcome if an effective method of blocking IL-10 is devised and delivered along with the desired cytokine. Fortunately, the effects of tumor-induced IL-10 that we observe in our system are local rather than global (Fig. 6)
. Therefore, other immunotherapeutic approaches such as vaccination strategies that deliver tumor antigens at sites distant from the primary tumor, and thus away from tumor-induced IL-10, are less likely to be affected.
In summary, our studies lend support to the hypothesis that production/induction of IL-10 by tumor cells may reflect an escape mechanism used by tumor cells to avoid destruction by the immune system. These findings highlight the importance of considering tumor-induced IL-10 in the design of immunotherapeutic strategies aimed at generating tumor-specific cell-mediated immunity and suggest that neutralization of IL-10 may be key to the effectiveness of such therapies.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported by USPHS Grants CA-42908 and CA-09683. 
2 To whom requests for reprints should be addressed, at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901.
3 The abbreviations used are: IL, interleukin; APC, antigen-presenting cell; KO, knockout; pfu, plaque-forming unit(s); DC, dendritic cell; BCG, Bacillus Calmette-Guérin.
Received 9/ 2/98. Accepted 12/14/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, granulocyte-macrophage colony-stimulating factor, and -interferon gene or admixed with conventional adjuvants. Cancer Res., 54: 6022-6026, 1994.This article has been cited by other articles:
|
|
 |
|
  D. A. Zaharoff, B. S. Hoffman, H. B. Hooper, C. J. Benjamin Jr., K. K. Khurana, K. W. Hance, C. J. Rogers, P. A. Pinto, J. Schlom, and J. W. Greiner Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12 Cancer Res., August 1, 2009; 69(15): 6192 - 6199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zeni, L. Mazzetti, D. Miotto, N. Lo Cascio, P. Maestrelli, P. Querzoli, M. Pedriali, E. De Rosa, L. M. Fabbri, C. E. Mapp, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Eur. Respir. J., October 1, 2007; 30(4): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Elliott, R. A. Scolyer, S. Suciu, S. Lebecque, D. Rimoldi, O. Gugerli, E. Musat, R. N. Sharma, D. Lienard, U. Keilholz, et al. Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma Clin. Cancer Res., July 1, 2007; 13(13): 3825 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Meeran, S. K. Mantena, S. Meleth, C. A. Elmets, and S. K. Katiyar Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol. Cancer Ther., April 1, 2006; 5(4): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, et al. Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses J. Immunol., July 15, 2005; 175(2): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion Cancer Res., December 15, 2004; 64(24): 9124 - 9130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Loskog, H. Dzojic, S. Vikman, C. Ninalga, M. Essand, O. Korsgren, and T. H. Totterman Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment J. Immunol., June 1, 2004; 172(11): 7200 - 7205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease Cancer Res., March 15, 2004; 64(6): 2205 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Hsiao, K.-W. Liao, S.-W. Hung, and R.-M. Chu Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-{beta}1 and Restores the Lymphokine-Activated Killing Activity J. Immunol., February 1, 2004; 172(3): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Yang, C. E. Monken, and E. C. Lattime Intratumoral Vaccination with Vaccinia-Expressed Tumor Antigen and Granulocyte Macrophage Colony-Stimulating Factor Overcomes Immunological Ignorance to Tumor Antigen Cancer Res., October 15, 2003; 63(20): 6956 - 6961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Yang and E. C. Lattime Tumor-induced Interleukin 10 Suppresses the Ability of Splenic Dendritic Cells to Stimulate CD4 and CD8 T-Cell Responses Cancer Res., May 1, 2003; 63(9): 2150 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, B. Gardner, B. Escuadro, K. Atianzar, D. P. Tashkin, and S. M. Dubinett IL-10 Mediates Sigma1 Receptor-Dependent Suppression of Antitumor Immunity J. Immunol., April 1, 2003; 170(7): 3585 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-X. Wang, B.-G. Chen, and G. E. Plautz Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion J. Immunol., September 15, 2002; 169(6): 3314 - 3320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dorsey, N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN-{gamma} Cancer Res., May 1, 2002; 62(9): 2606 - 2610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Segal, D. D. Glass, and E. M. Shevach Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection J. Immunol., January 1, 2002; 168(1): 1 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, M. Stolina, L. Zhu, Y. Lin, R. Batra, M. Huang, R. Strieter, and S. M. Dubinett Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma Cancer Res., September 1, 2001; 61(17): 6406 - 6412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Grimm, C. M. Smid, J. J. Lee, C.-H. Tseng, O. Eton, and A. C. Buzaid Unexpected Cytokines in Serum of Malignant Melanoma Patients during Sequential Biochemotherapy Clin. Cancer Res., October 1, 2000; 6(10): 3895 - 3903. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. V. Kotenko, S. Saccani, L. S. Izotova, O. V. Mirochnitchenko, and S. Pestka Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10) PNAS, February 15, 2000; 97(4): 1695 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sica, A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. V. Damme, and A. Mantovani Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF-{kappa}B Activation in Tumor-Associated Macrophages J. Immunol., January 15, 2000; 164(2): 762 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stolina, S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis J. Immunol., January 1, 2000; 164(1): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
